of biotechnology company Novavax stand to collect millions even if their vaccine never makes it to the market. The stock options earmarked for CEO Stanley Erck and three other executives EFTA00025450 --- PAGE BREAK --- are worth more than $100 million. They're contingent on the vaccine making it to a Ph